Search Results - "Pitt, Bertram"

Reassessing the management of hypertension: Time to prevent aldosterone‐mediated heart failure.

Authors: Pitt, Bertram Brown, Jenifer M. Vaidya, Anand et al.

Source: European Journal of Heart Failure. Feb2024, Vol. 26 Issue 2, p195-198. 4p.

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.

Authors: Agarwal, Rajiv Pitt, Bertram Palmer, Biff F et al.

Source: Clinical Kidney Journal. Feb2023, Vol. 16 Issue 2, p293-302. 10p.

The use of mineralocorticoid receptor antagonists for patients with heart failure with a reduced ejection fraction: A time for reassessment.

Authors: Pitt, Bertram Zannad, Faiez

Source: European Journal of Heart Failure. Dec2023, Vol. 25 Issue 12, p2174-2176. 3p.

Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial.

Authors: Cunningham, Jonathan W. Claggett, Brian L. Vaduganathan, Muthiah et al.

Source: European Journal of Heart Failure. Aug2025, Vol. 27 Issue 8, p1487-1491. 5p.

Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial.

Authors: Chimura, Misato Yang, Mingming Henderson, Alasdair D. et al.

Source: European Journal of Heart Failure. Nov2025, Vol. 27 Issue 11, p2301-2312. 12p.

Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!

Authors: Rossignol, Patrick Pitt, Bertram

Source: Clinical Kidney Journal. Aug2023, Vol. 16 Issue 8, p1221-1225. 5p.

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis.

Authors: Mentz, Robert J. Anker, Stefan D. Pitt, Bertram et al.

Source: European Journal of Heart Failure. May2025, Vol. 27 Issue 5, p764-774. 11p.

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial.

Authors: Filippatos, Gerasimos Pitt, Bertram Agarwal, Rajiv et al.

Source: European Journal of Heart Failure. Jun2022, Vol. 24 Issue 6, p996-1005. 10p. 1 Color Photograph, 2 Charts, 3 Graphs.

Are Diuretics a Clandestine Risk Factor for Patients With Treatment-Resistant Hypertension?

Authors: Pitt, Bertram Wilcox, Christopher S.

Source: Hypertension (0194911X). Aug2025, Vol. 82 Issue 8, p1271-1276.

Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight.

Authors: Butt, Jawad H. Solomon, Scott D. Vaduganathan, Muthiah et al.

Source: European Journal of Heart Failure. Dec2025, Vol. 27 Issue 12, p2810-2815. 6p.

Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial.

Authors: Solomon, Scott D. Ostrominski, John W. Vaduganathan, Muthiah et al.

Source: European Journal of Heart Failure. Jun2024, Vol. 26 Issue 6, p1334-1346. 13p.

Knowledge domains and emerging trends in aldosterone and kidney disease prognosis: a bibliometric analysis.

Authors: Jiang W Wang M Yang W et al.

Source: International urology and nephrology [Int Urol Nephrol] 2026 Mar; Vol. 58 (3), pp. 1053-1068. Date of Electronic Publication: 2025 Sep 11.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: Netherlands NLM ID: 0262521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2584 (Electronic) Linking ISSN: 03011623 NLM ISO Abbreviation: Int Urol Nephrol Subsets: MEDLINE

Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from 'real‐world' evidence?

Authors: Rossignol, Patrick Pitt, Bertram

Source: European Journal of Heart Failure. Mar2023, Vol. 25 Issue 3, p361-363. 3p.

On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF.

Authors: Kittipibul, Veraprapas Mentz, Robert J. Clare, Robert M. et al.

Source: European Journal of Heart Failure. Jul2024, Vol. 26 Issue 7, p1518-1523. 6p.

Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?

Authors: Rossignol, Patrick Pitt, Bertram

Source: European Journal of Heart Failure. Apr2022, Vol. 24 Issue 4, p631-633. 3p.

Towards a better prevention in cardio-kidney metabolic syndrome: Role of aldosterone and albuminuria.

Alternate Title: Hacia una mejor prevenció n del síndrome cardiorrenometabó lico: papel de la aldosterona y la albuminuria.

Authors: Ruilope, Luis M. Pitt, Bertram de la Sierra, Alejandro et al.

Source: Nefrologia. Nov2025, Vol. 45 Issue 9, p1-2. 2p.

Subjects: ALDOSTERONE, ALBUMINURIA, CARDIO-renal syndrome

When chronic kidney disease (CKD) intersects with heart failure: Insights and implications of the identification of KDIGO‐defined CKD in 1.4 million U.S. Veterans with heart failure.

Authors: Pitt, Bertram Rossignol, Patrick

Source: European Journal of Heart Failure. Jul2024, Vol. 26 Issue 7, p1652-1654. 3p.

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial.

Authors: Butt, Jawad H. Jhund, Pardeep S. Henderson, Alasdair D. et al.

Source: European Journal of Heart Failure. Jul2025, Vol. 27 Issue 7, p1326-1341. 16p.

New opportunity for targeting systemic inflammation in patients with heart failure through leucocyte immunomodulation.

Authors: Pitt, Bertram Iyer, Sai Prasad N. Humes, H. David

Source: European Journal of Heart Failure. Mar2024, Vol. 26 Issue 3, p534-536. 3p.

Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM‐HF trial.

Authors: Nouhravesh, Nina Greene, Stephen J. Clare, Robert et al.

Source: European Journal of Heart Failure. Feb2025, Vol. 27 Issue 2, p317-324. 8p.